![Public 6](/var/esmo/storage/images/media/esmo-daily-reporter/images/generic-pictures-live/public-6/9274557-1-eng-GB/public-6_i770.jpg)
Patient-reported outcomes favour first-line three-drug combination in metastatic NSCLC
Health-related quality of life data from the POSEIDON study support previous efficacy findings for the benefits of a two-agent immunotherapy regimen plus chemotherapy over chemotherapy alone